Conditionally **A**ctive **B**iologics: Transforming Cancer Therapy

Jefferies Global Healthcare Conference

June 2022

bioatla

Important Notices & Disclaimers

This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, results of clinical trials and other future conditions. Words such as, but not limited to, "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will", "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements.

These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties, including those described in the Company's filings with the SEC, including but not limited to the Company's latest Annual Report on Form 10-K. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company qualifies all the forward-looking statements in this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Statements contained herein are made as of the date of this Presentation unless stated otherwise, and this Presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof.

Certain information contained in this Presentation relates to or is based on statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as the Company's own estimates of the prevalence of certain diseases and conditions. The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. The Company's estimates of the patient population with the potential to benefit from treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and third-party research, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions.

This Presentation may contain trademarks, trade names, or service marks belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, or by these other parties.

None of the Company or any of its directors, officers, employees, contractors, agents, consultants, advisors or other representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in this Presentation.

BioAtla© is a clinical stage company focused on transforming cancer therapy

with **C**onditionally **A**ctive **B**iologics (CABs)



Selective and targeted CAB technology widens therapeutic index,

thus has the potential to enhance clinical outcomes in multiple tumor types

- BioAtla discovered that acidic pH at the cancer cell surface unveils binding sites that are shielded at normal pH of healthy cells
- BioAtla invented CAB technology, creating antibodies that bind ***only*** to these unveiled sites on cancer cells
- CAB binding region is not masked or caged and thus different from prodrugs that require irreversible enzymatic cleavage to become activated
- CAB antibodies have the potential for increased efficacy with improved safety relative to traditional antibodies



Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L, Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19.

Focused pipeline with broad applicability of differentiated CAB assets designed to deliver near-term value

	CAB Program	Target	Indications	IND Enabling Pre-Clinical	Phase 1 Clinical	Phase 2 Clinical	Anticipated Milestones
CAB-ADCs	**BA3011** *Mecbotamab Vedotin*	AXL	• STS & Bone Sarcoma • NSCLC • Ovarian Cancer*				✓ Interim sarcoma update Q1 earnings • Phase 2 interim NSCLC clinical data Q2 earnings ✓ Ovarian IIT dosing 1H22
CAB-ADCs	**BA3021** *Ozuriftamab Vedotin*	ROR2	• NSCLC • Melanoma • SCCHN • Ovarian Cancer*				• Phase 2 interim NSCLC and melanoma data mid-year / 2H22 • SCCHN trial dosing 1H22 ✓ Ovarian IIT dosing 1H22
CAB-I/O	**BA3071**	CTLA-4	• Mutiple tumor types**				• Trial dosing 1H22
CAB-Bi-specifics	**BA3182**	EpCAM & CD3	• Adenocarcinoma** • Multiple tumor types**				• IND submission and Phase 1 initiation 2022
	Additional programs	Various	• Multiple tumor types**				• 2023 and beyond

** Phase 2 investigator-initiated trial for Ovarian Cancer ** Indications based upon tumor target expression*

IIT, investigator-initiated trial; IND, investigational new drug; NSCLC, Non-small Cell Lung Cancer; RCC, Renal Cell Carcinoma; SCCHN, Squamous Cell Carcinoma of the Head and Neck; STS, Soft Tissue Sarcoma.



Sarcoma Cells

CAB-AXL-ADC Platform

BA3011 Mecbotamab Vedotin: Sarcoma and NSCLC

Significant opportunity for BA3011 in Sarcoma and NSCLC

to fill unmet medical needs

Current treatments for AXL+ tumors are insufficient, leading to high recurrence rates, rapid progression, low survival rates, and drug-related toxicities

Our Phase 1 studies revealed positive clinical signals across sarcoma and NSCLC, demonstrated by durable clinical responses (PFS and PR), and reductions in tumor size

We have two ongoing Phase 2 studies in sarcoma and NSCLC

We are excited to advance towards our transition to commercial-stage company while filling a significant unmet medical need for patients with AXL+ solid tumors

NSCLC, non-small cell lung cancer; PFS, progression-free survival; PR, partial response.

Sarcoma: Encouraging Phase 2 Part 1 Topline Interim Analysis Results



Interim results satisfied pre-defined ‘Go’ criteria into part 2 of the Phase 2 BA3011 study in both UPS and Osteosarcoma

Pre-defined criteria for each subgroup up to 10 patients: ‘No Go’ if 0 CR/PR and PFS rate at 12 weeks <40%; ‘Go’ if ≥1 CR/PR or PFS rate at 12 weeks ≥40%. * As of data cut-off of Apr 28, 2022; Cohorts in grey continuing enrollment until sufficient sample size is achieved. **Included in UPS cohort. BA3011 dose 1.8 mg/kg Q2W. Inclusion criteria: measurable disease, ECOG performance status 0 or 1. PFS, progression-free survival; PR, partial response; UPS, undifferentiated pleomorphic sarcoma.

Continued promising safety and tolerability profile

observed in Phase 2 at the RP2D

No treatment-related deaths

Few treatment-related SAEs, consistent with MMAE-based toxicity, including: Reversible myelosuppression, Transient liver enzyme elevation, Metabolic disturbances

Few related AEs leading to treatment discontinuation

No clinically meaningful on-target toxicity observed over background

Differentiated profile due to avoiding on-target off-tumor toxicity

Encouraging Phase 1 results enables initiation of Phase 2 study in NSCLC

- A partial response was achieved in the AXL-high NSCLC patient refractory to multiple chemo PKIs and pembrolizumab failure

Phase 2 study and enrollment in refractory NSCLC patients:

Initial interim analysis

- AXL+ ≥1 TmPS
- Monotherapy and Combination with PD-1/L1
- After ~20 pts complete 2 scans

Next step

- If definitive, move into part 2 or stop program
- Ability to continue enrollment up to ~40 patients, if desired

Phase 2 part 2

- Combination (BA3011+Opdivo)
- Monotherapy (BA3011)
- n=100 per arm

Endpoints

Primary endpoints

- Confirmed ORR per RECIST v1.1
- AEs or SAEs

Secondary endpoints

- DOR, PFS, ORR, DCR, TTR, OS

BA3011 dose 1.8 mg/kg Q2W. Inclusion criteria: measurable disease, ≥ 18 years, ECOG performance status 0 or 1.
AE, adverse event; BOR, best overall response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SAE, serious adverse event; TTR, time to response.

CAB-ROR2-ADC Platform

BA3021 Ozuriftamab Vedotin – NSCLC and Melanoma

Encouraging Phase 1 results with BA3021 support advancing into Phase 2 in multiple indications

No ROR2 ADC or small molecules in the clinic to date, suggesting CAB-ROR2-ADC is potentially a first-in-class therapy across multiple tumor types

Phase 1 study

- NSCLC: PR (n= 2 / 3* ROR2+)
- Melanoma: CR (n= 1 / 1 ROR2+) - clearance of pulmonary metastases followed by normalization of adenopathy and continued CR off treatment for over 2 years
- SCCHN: PR (n= 1 / 1 ROR2+ PD-1/cetuximab refractory patient)
- Promising safety and tolerability profile across multiple tumor types

Phase 2 studies

- NSCLC ROR2+ patients w/ TmPS ≥1%; refractory to PD-1, EGFR, or ALK; mono & combination w/ PD-1; sample size n=40
- Melanoma ROR2+ patients w/ TmPS ≥1%; refractory to PD-1; mono & combination w/ PD-1; sample size n=40
  - CR (n= 1 / 1) on 1st scan, 3 doses
- SCCHN ROR2+ patients w/ TmPS ≥1%; refractory to PD-1 alone or in combination with platinum; mono & combination w/ PD-1; sample size n=40

*ROR2+ patients who received Ph2 dose or higher

A number of key upcoming milestones in 2022

Program	Indications	2022	
		1H	2H
BA3011 *Mecbotamab Vedotin*	STS and bone sarcoma	✓ Phase 2 interim update	☆ Phase 2 part 2 initiation
	NSCLC	☆ Phase 2 interim data	
	Ovarian*	✓ Phase 2 IIT dosing	
BA3021 *Ozuriftamab Vedotin*	NSCLC		☆ Phase 2 interim data
	Melanoma		☆ Phase 2 interim data
	SCCHN	☆ Phase 2 dosing	
	Ovarian*	✓ Phase 2 IIT dosing	
BA3071	Multiple tumor types**	☆ Phase 1 / 2 dosing	
BA3182	Adenocarcinoma** Multiple tumor types**		☆ IND submission / Phase 1 initiation

CAB-ADCs | CAB-I/O | CAB-Bispecifics

*Phase 2 Investigator-initiated trial combination with PD-1 (n=60) in platinum failure patients. Initial sites activated. **Anticipated indications based upon tumor target expression.

BioAtla© is a clinical stage company focused on transforming cancer therapy

with **C**onditionally **A**ctive **B**iologics (CABs)



Execute on clinical programs

Create long-term sustainable value

Build core commercial capabilities

Conditionally **A**ctive **B**iologics: Transforming Cancer Therapy

Jefferies Global Healthcare Conference

June 2022

bioatla